The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.本發明係關於適用於人類癌症治療之重組抗體領域。更特定言之，本發明提供能夠結合人類EGFR之抗體的組成物或混合物。具有3種或3種以上抗體之抗體組成物展示使代表性癌細胞株增殖減少之協同作用。使用包含兩種不同嵌合抗hEGFR抗體之組成物亦獲得有利結果，其在動物模型中展示基於迅速及有效受體內化、誘導終末分化及後續腫瘤根除之新的作用機制。本發明之抗體可在一生物反應器中以多株抗體形式製備。
